(Q61456224)

21

object named as

Yaomin Xu

0 references

author name string

Douglas B Johnson

1

0 references

Mellissa J Nixon

2

0 references

Yu Wang

3

0 references

Daniel Y Wang

4

0 references

Emily Castellanos

5

0 references

Monica V Estrada

6

0 references

Paula I Ericsson-Gonzalez

7

0 references

Candace H Cote

8

0 references

Roberto Salgado

9

0 references

Violeta Sanchez

10

0 references

Phillip T Dean

11

0 references

Susan R Opalenik

12

0 references

Daniel M Schreeder

13

0 references

David L Rimm

14

0 references

Ju Young Kim

15

0 references

Jennifer Bordeaux

16

0 references

Sherene Loi

17

0 references

Leora Horn

18

0 references

Melinda E Sanders

19

0 references

P Brent Ferrell

20

0 references

Jeffrey A Sosman

22

0 references

Randall S Davis

Characterization of the lymphocyte activation gene 3-encoded protein. A new ligand for human leukocyte antigen class II antigens

23

0 references

language of work or name

English

0 references

publication date

20 December 2018

0 references

published in

JCI insight

0 references

volume

3

0 references

issue

24

0 references

cites work

1 reference

12 December 2020

HLA-DR histocompatibility leukocyte antigens permit cultured human melanoma cells from early but not advanced disease to stimulate autologous lymphocytes

1 reference

12 December 2020

Lymphocyte-activation gene 3/major histocompatibility complex class II interaction modulates the antigenic response of CD4+ T lymphocytes

1 reference

12 December 2020

Interaction of natural killer cells with MHC class II: reversal of HLA-DR1-mediated protection of K562 transfectant from natural killer cell-mediated cytolysis by brefeldin-A.

1 reference

12 December 2020

Regulation of a graft-versus-leukemia effect by major histocompatibility complex class II molecules on leukemia cells: HLA-DR1 expression renders K562 cell tumors resistant to adoptively transferred lymphocytes in severe combined immunodeficiency mi

1 reference

12 December 2020

Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery

1 reference

12 December 2020

Tumor rejection by gene transfer of the MHC class II transactivator in murine mammary adenocarcinoma cells.

1 reference

12 December 2020

The inhibitory potential of Fc receptor homolog 4 on memory B cells

1 reference

12 December 2020

Tumor cells transduced with the MHC class II Transactivator and CD80 activate tumor-specific CD4+ T cells whether or not they are silenced for invariant chain

1 reference

12 December 2020

CIITA-induced MHC class II expression in mammary adenocarcinoma leads to a Th1 polarization of the tumor microenvironment, tumor rejection, and specific antitumor memory.

1 reference

12 December 2020

Fc receptor-like molecules

1 reference

12 December 2020

FcRL6, a new ITIM-bearing receptor on cytolytic cells, is broadly expressed by lymphocytes following HIV-1 infection

1 reference

12 December 2020

Measurement of cytotoxic activity of NK/LAK cells

1 reference

12 December 2020

FCRL6 distinguishes mature cytotoxic lymphocytes and is upregulated in patients with B-cell chronic lymphocytic leukemia

1 reference

12 December 2020

Cutting edge: FcR-like 6 is an MHC class II receptor

1 reference

12 December 2020

Web-based analysis and publication of flow cytometry experiments

1 reference

12 December 2020

CXCR3 in T cell function

1 reference

12 December 2020

Introduction of the CIITA gene into tumor cells produces exosomes with enhanced anti-tumor effects

1 reference

12 December 2020

RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome

1 reference

12 December 2020

A platinum-based covalent viability reagent for single-cell mass cytometry.

1 reference

12 December 2020

The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data

1 reference

12 December 2020

RSeQC: quality control of RNA-seq experiments

1 reference

12 December 2020

Comprehensive molecular portraits of human breast tumours

1 reference

12 December 2020

STAR: ultrafast universal RNA-seq aligner

1 reference

12 December 2020

viSNE enables visualization of high dimensional single-cell data and reveals phenotypic heterogeneity of leukemia

1 reference

12 December 2020

T cells at the site of autoimmune inflammation show increased potential for trogocytosis

1 reference

12 December 2020

Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets

1 reference

12 December 2020

Nonclassical antigen-processing pathways are required for MHC class II-restricted direct tumor recognition by NY-ESO-1-specific CD4(+) T cells

1 reference

12 December 2020

How Do CD4(+) T Cells Detect and Eliminate Tumor Cells That Either Lack or Express MHC Class II Molecules?

1 reference

12 December 2020

Automated identification of stratifying signatures in cellular subpopulations

1 reference

12 December 2020

Genomic mapping of the MHC transactivator CIITA using an integrated ChIP-seq and genetical genomics approach

1 reference

12 December 2020

Genetic basis for clinical response to CTLA-4 blockade in melanoma

1 reference

12 December 2020

Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

1 reference

12 December 2020

Neoantigens in cancer immunotherapy.

1 reference

12 December 2020

Mapping RNA-seq Reads with STAR

1 reference

12 December 2020

Genomic correlates of response to CTLA-4 blockade in metastatic melanoma

1 reference

12 December 2020

RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors

1 reference

12 December 2020

Cancer immunotherapy targeting neoantigens

1 reference

12 December 2020

Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy.

1 reference

12 December 2020

Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints.

1 reference

12 December 2020

PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations

1 reference

12 December 2020

Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma

1 reference

12 December 2020

Triple-negative breast cancers with amplification of JAK2 at the 9p24 locus demonstrate JAK2-specific dependence.

1 reference

12 December 2020

The Ensembl gene annotation system

1 reference

12 December 2020

Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma

1 reference

12 December 2020

Antitumor Effect of Programmed Death-1 (PD-1) Blockade in Humanized the NOG-MHC Double Knockout Mouse.

1 reference

12 December 2020

CD4+ T cell-mediated cytotoxicity eliminates primary tumor cells in metastatic melanoma through high MHC class II expression and can be enhanced by inhibitory receptor blockade.

1 reference

12 December 2020

Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations

1 reference

12 December 2020

CIITA-driven MHC class II expressing tumor cells can efficiently prime naive CD4+ TH cells in vivo and vaccinate the host against parental MHC-II-negative tumor cells

1 reference

12 December 2020

PD-1 and PD-L1 antibodies in cancer: current status and future directions

1 reference

12 December 2020

Clinical Features of Acquired Resistance to Anti-PD-1 Therapy in Advanced Melanoma.

1 reference

12 December 2020

Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma.

1 reference

12 December 2020

MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma

1 reference

12 December 2020

Quantitative Spatial Profiling of PD-1/PD-L1 Interaction and HLA-DR/IDO-1 Predicts Improved Outcomes of Anti-PD-1 Therapies in Metastatic Melanoma

1 reference

12 December 2020